ProMetic Life Sciences Inc. announced that it has received a $2.5 million purchase order under its ongoing supply agreement with Octapharma. This purchase order further confirms the binding forecast received from Octapharma and is in addition to the $0.73 million order announced in October 2011. More than $3.0 million of shipments to Octapharma are expected during the first half of 2012. This order relates to the purchase of PrioClear(TM), a proprietary prion capture resin incorporated into Octapharma's manufacturing process for its solvent/detergent treated plasma product, Octaplas(R)LG. Octaplas(R)LG is currently approved for marketing in several European countries and the object of ongoing procedures for its regulatory approval for the North American market. Further binding forecast of the same magnitude for the second half of 2012 is expected at a later time during the first half of 2012.